Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan. - Effect of tolvaptan on refractory ascites.

The third department of internal medicine, Nara Medical University0 个研究点目标入组 300 人开始时间: 2017年2月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Adequate cardiac organ function a) Patients with conjestive heart failure above NYHA class3 b) Patients with severe hypertension 2) Patients with severe and active infectious disease (exclude HBV,HCV hepatitis) 3) Patients with HIV 4) Patients taking dialysis 5) Patients with portal tumor thrombosis (Vp3 or Vp4) 6) Patients with hepatic encephalopathy 7) Patients with crutial digestive bleedings within 4 weeks 8) Patients with the following treatment a) Systemic chemotherapy b) Being treated with invasive surgical therapy within 4 weeks 9) Patients with oral intake difficulty 10)Patients with severe digestive diseases 11)Patients taking a tablet which would affect this clinical study 12)Pregnant woman, lactating woman, or a woman suspected of pregnancy 13)Patients with severe allergic reaction to Tolvaptan 14)Patients with drug abuse or psycological disorders 15) Patients concluded to be inappropriate to participate in this study by their physitians

发起方

The third department of internal medicine, Nara Medical University